Key facts
- Protalys Therapeutics’s last known valuation is $32.7M (Aug 2025).
- It has raised $18.7M; the latest was Seed Round ($18.7M) in Aug 2025.
- Notable investors include Avalon Bioventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Protalys Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Protalys Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Protalys Therapeutics
Developer of a therapeutic delivery technology intended to improve the performance of targeted protein degradation agents. The company employs established in situ carriers to transport small-molecule degraders into solid tumors, enhancing pharmacokinetics, addressing limitations of difficult targets, enabling the rescue of previously ineffective degraders, and supporting expanded discovery opportunities in oncology.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Ownership
- Privately Held (backing)
Protalys Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Protalys Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Protalys Therapeutics in its N-PORT filings yet. We sweep new filings monthly.